Last update Oct. 11, 2017

D07AB09

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A corticosteroid with a mainly glucocorticoid action and moderate anti-inflammatory effects (ATC D07AB), slightly higher than that of prednisolone (ATC D07AA).
Its topical dermatological use is indicated in the treatment of various types of dermatitis.

This comment is about the TOPICAL USE of triamcinolone.

Limited absorption through the skin and even mucous (Ramadas 2016, Meynadier 1981, Rasmussen 1978) makes it unlikely that significant amounts will pass into breast milk.

If it is required to treat eczema or dermatoses of the nipple, it is advisable to choose the mildest corticoid, apply it just after the feed is finished so that it has been reabsorbed before the next feed, if it is necessary residues can be removed with a gauze and do not use it for more than a week after.

Mineralocorticoid intoxication has occurred in an infant due to continuous application of a corticoid to the nipple (De Stefano 1983).

It is advisable to avoid application to the nipple of creams, gels and other topically-applied products that contain paraffin (mineral oil) so that the infant does not absorb them (Concin 2008, Noti 2003).


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

D07AB09 is Triamcinolone (topical use) in ATC Code/s.

Group

D07AB09 belongs to this group or family:

Tradenames

Main tradenames from several countries containing D07AB09 in its composition:

  • Aldoderma™. Contains other elements than D07AB09 in its composition
  • Anso™. Contains other elements than D07AB09 in its composition
  • Positon™. Contains other elements than D07AB09 in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor (dermat) %
Molecular weight 394 daltons
Protein Binding 68 %
VD 1.4 l/Kg
pKa 13.4 -
T½ 2 hours

References

  1. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 0.1% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016 Abstract
  2. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  3. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  4. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract
  5. Meynadier J, Guilhou JJ, Peyron JL. [Percutaneous absorption of triamcinolone 16 alpha, 17 alpha cyclopentylene-dioxy-21-acetate (author's transl)]. Dermatologica. 1981 Abstract
  6. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol. 1978 Abstract

Total visits

1,271

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM